Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain

作者
Stefano De Santis,Maria Domenica Simone,Sebastiano Mercadante,Rocco Domenico Mediati,Renato Vellucci,Paolo Marchetti,Giuseppe Tonini,Arturo Cuomo,Augusto Caraceni,Silvia Natoli,Grazia Armento,Livio Blasi,Massimo Mammucari
出处
期刊:Cancer management and research [Dove Medical Press]
卷期号:Volume 13: 1747-1756 被引量:9
标识
DOI:10.2147/cmar.s290551
摘要

Background: International guidelines recommend moderate-to-severe cancer pain to be treated with strong opioids. However, pain management remains an unsolved matter, at least in the demanding oncology and palliative care setting. Although cancer pain consists of multiple components, which interact in complex ways where combination therapy can better intercept multiple pain characteristics, few studies have used a non-opioid/opioid association to exploit possible synergistic actions. Even the efforts of a recent approach emphasizing appropriate pain assessment and accurate classification to obtain personalized pain management have not produced a satisfactory analgesic strategy. Objective: This analysis was intended to evaluate the effectiveness of the immediate release fixed combination of oxycodone/acetaminophen (OxyIR/Par) for the treatment of moderate-to-severe intensity background pain used alone or in combination with other strong opioids in cancer patients with breakthrough cancer pain (BTcP). This is a secondary analysis of a wider observational, prospective, multicenter study [Italian Oncologic Pain multiSetting Multicentric Survey (IOPS-MS)] performed on 179 patients treated with opioids for cancer pain who received the fixed combination of oxycodone/acetaminophen (OxyIR/Par) for the treatment of background pain (BGP). Results: Cancer patients with breakthrough cancer pain and controlled BGP (Background Pain) were classified according to the presence of analgesic therapy with tablets of fixed combination OxyIR/Par alone (group A, n=120) or tablets of fixed combination OxyIR/Par combined with other strong opioids (group B, n=59). Clinical features of group A were different to group B: higher mean Karnofsky Performance Status Index 70.3% (95% CI=67.2– 73.5; median=70, CI=60– 80) vs 58.3 (95% CI=53.4– 63.2; median=50, CI=45– 70) ( P < 0.001), and mainly group A patients were treated in an ambulatory setting (55.0% group A vs 33.9% group B) (p< 0.001). Both groups had managed BGP with similar mean dosages (group A: 12.0, CI=10.5– 13.4; group B: 13.1, CI=11.0– 15.1) and frequencies of OxyIR/Par alone for group A and in association to other opioids for group B, but Breakthrough cancer Pain (BTcP) exhibited different characteristics in the two groups, showing a lower mean intensity numerical rating scale (NRS) of 7.5 (95% CI=7.2– 7.7; median=7, CI=7– 8 group A) vs 7.9 (95% CI=7.6, 8.2; median= 8, CI=7– 9 group B) ( P =0.04) and a higher percentage of patients had a faster onset, defined as the maximum intensity reached in less than 10 minutes, 81.7% (N=98) in group A vs 59.3% (n=35) in group B ( P =0.002). Conclusion: This is the first analysis about the efficacy of an immediate-release fixed combination of OxyIR/Par in the real world for moderate-to-severe background cancer pain and breakthrough cancer pain. The oral fixed combination OxyIR/Par provided an adequate level of analgesia for moderate–severe background cancer pain, in a different cohort of cancer patients with different performance status, both in ambulatory and palliative settings. The low dosage of fixed combination OxyIR/Par was effective alone or in association with other opioids. Keywords: analgesia, combination of oxycodone/acetaminophen, cancer pain, breakthrough cancer pain

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
吃草草没完成签到,获得积分10
1秒前
1秒前
1秒前
海绵小方块完成签到,获得积分10
1秒前
谨岛嗦的应助被听海与你采纳,获得10
1秒前
南辞完成签到 ,获得积分10
2秒前
LIUYC完成签到,获得积分10
3秒前
christy发布了新的文献求助10
3秒前
moon完成签到 ,获得积分10
3秒前
3秒前
任性的沅完成签到,获得积分10
3秒前
吴境完成签到,获得积分20
4秒前
张伟发布了新的文献求助10
4秒前
李木子完成签到 ,获得积分10
4秒前
4秒前
SciGPT的应助被zxd采纳,获得10
4秒前
4秒前
隐形曼青的应助被糟糕的电脑采纳,获得10
4秒前
怜熙完成签到,获得积分10
4秒前
天涯过客完成签到,获得积分10
5秒前
隐形曼青的应助被WEN采纳,获得10
5秒前
乐乐的应助被可妍昇采纳,获得10
5秒前
起早完成签到,获得积分20
5秒前
Owen的应助被熬夜的小王采纳,获得10
5秒前
inghai发布了新的文献求助10
5秒前
张兆阳发布了新的文献求助10
5秒前
小黑球发布了新的文献求助100
6秒前
6秒前
fenfen完成签到 ,获得积分10
6秒前
123完成签到,获得积分10
6秒前
共享精神的应助被材料牛马采纳,获得10
7秒前
蔓越莓完成签到 ,获得积分10
7秒前
7秒前
huhuhu完成签到,获得积分10
8秒前
张文凯发布了新的文献求助10
8秒前
8秒前
8秒前
Zhang完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253